Respiratory Diseases Drugs Global Market Report 2018

1. Respiratory Diseases Drugs Global Market Report 2018 Including: Anti-Asthmatics And COPD Drugs; Cough And Cold Preparations Covering: GlaxosmithKline Plc, AstraZeneca Plc, Merck & Co., Novartis AG, Johnson & Johnson Feb 2018

2. Reasons to Purchase • Outperform competitors using accurate up to date demand-side dynamics information. • Identify growth segments for investment. • Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market. • Create regional and country strategies on the basis of local data and analysis. • Stay abreast of the latest customer and market research findings • Benchmark performance against key competitors. • Develop strategies based on likely future developments. • Utilize the relationships between key data sets for superior strategizing. • Suitable for supporting your internal and external presentations with reliable high quality data and analysis • Gain a global perspective on the development of the market. • Report will be updated with the latest data and delivered to you within 3-5 working days of order. Scope Markets Covered: Anti-Asthmatics And COPD Drugs; Cough And Cold Preparations Companies Mentioned: GlaxosmithKline Plc, AstraZeneca Plc, Merck & Co., Novartis AG, Johnson & Johnson Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia. Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa Time series: Five years historic and forecast. Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, Respiratory Diseases Drugs Indicators Comparison. Data segmentations: Country and regional historic and forecast data, market share of competitors, market segments. Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

3. Respiratory Diseases Drugs Respiratory Diseases Drugs Market Characteristics Market Characteristics Respiratory diseases drugs market covers drugs that are used in the treatment of a wide range of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), chronic and acute bronchitis, emphysema and cystic fibrosis. Some of the major drugs in the market include antimuscarinics, corticosteroids, Codral®, Coldrex® and Lemsip®. The segments that are covered include – Anti-Asthmatics And COPD Drugs – Cough And Cold Preparations – In this report market value is defined as the revenues organizations earn by selling their goods and services within the specified market, based on the price at which they sell. Only goods and services traded between entities are included. The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced.

4. Respiratory Diseases Drugs Respiratory Diseases Drugs Market Market Historic Growth Historic Growth The global respiratory diseases drugs market grew from $X billion in 2013 to $X billion in 2017 at a compound annual growth rate (CAGR) of X%. The chart and table below shows the year-on-year growth of the global respiratory diseases drugs market during 2013 – 2017. Drivers of the Market: Restraints on the Market:

5. Respiratory Diseases Drugs Respiratory Diseases Drugs Market Forecast Growth Market Forecast Growth The global respiratory diseases drugs market grew from $XX billion in 2017 to $XX billion in 2021 at a compound annual growth rate (CAGR) of XX%. The chart and table below shows the year-on-year growth of the global respiratory diseases drugs market during 2017 - 2021. Drivers of the Market: Restraints on the Market:

6. Respiratory Diseases Drugs Respiratory Diseases Drugs Market Market Segmentation Segmentation The chart and table below shows the split of the respiratory diseases drugs market in 2017. The total market value for respiratory diseases drugs was $X billion in 2017. The markets that are covered include Anti-Asthmatics And COPD Drugs; Cough And Cold Preparations. Anti-Asthmatics And COPD Drugs was the X largest segment in the respiratory diseases drugs market with X% share of the market. The market value for the Anti- asthmatics and COPD drugs was $X billion in 2017. Cough And Cold Preparations made up around X% share of the market. The market value for the cough and cold preparations was $X billion in 2017.

7. Respiratory Diseases Drugs Respiratory Diseases Drugs Market Market Regional And Country Regional And Country Analysis Analysis The Asia Pacific was the largest region in the respiratory diseases drugs market in 2017, respiratory diseases drugs for $X billion or X% market share. North America was the x largest region respiratory diseases drugs for $X billion or X% market share. Western Europe was the x largest region respiratory diseases drugs for $X billion or X% market share.

8. Respiratory Diseases Drugs Respiratory Diseases Drugs Market Competitive Landscape Market Competitive Landscape The leading competitors in the global respiratory diseases drugs market are GlaxosmithKline Plc, AstraZeneca Plc, Merck & Co., Novartis AG, Johnson & Johnson. The chart and table below displays the percentage market share of the top players in the respiratory diseases drugs market industry. Company Profile GlaxosmithKline Plc Overview Products and Services Strategy Financial Performance

9. AstraZeneca Plc Overview Products and Services Strategy Financial Performance Merck & Co. Overview Products and Services Strategy Financial Performance Novartis AG Overview Products and Services Strategy Financial Performance Johnson & Johnson Overview Products and Services Strategy Financial Performance